Northern Trust’s Harvard Bioscience HBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-9,197
Closed -$61.5K 4464
2025
Q4
$61.5K Sell
9,197
-5,320
-37% -$31.6K ﹤0.01% 4236
2025
Q3
$63.7K Sell
14,517
-4,370
-23% -$20.7K ﹤0.01% 4236
2025
Q2
$83.8K Sell
18,887
-22,974
-55% -$96K ﹤0.01% 4149
2025
Q1
$237K Sell
41,861
-3,041
-7% -$38.9K ﹤0.01% 3879
2024
Q4
$947K Sell
44,902
-302
-0.7% -$6.94K ﹤0.01% 3419
2024
Q3
$1.22M Buy
45,204
+342
+0.8% +$10.1K ﹤0.01% 3273
2024
Q2
$1.28M Sell
44,862
-748
-2% -$26.2K ﹤0.01% 3139
2024
Q1
$1.93M Sell
45,610
-1,155
-2% -$51.9K ﹤0.01% 2982
2023
Q4
$2.5M Buy
46,765
+94
+0.2% +$4.24K ﹤0.01% 2875
2023
Q3
$2.01M Buy
46,671
+531
+1% +$24.5K ﹤0.01% 2936
2023
Q2
$2.53M Buy
46,140
+26,910
+140% +$1.48M ﹤0.01% 2874
2023
Q1
$808K Buy
19,230
+138
+0.7% +$4.09K ﹤0.01% 3288
2022
Q4
$529K Sell
19,092
-63
-0.3% -$1.55K ﹤0.01% 3485
2022
Q3
$490K Sell
19,155
-42,257
-69% -$1.4M ﹤0.01% 3516
2022
Q2
$2.21M Buy
61,412
+15,764
+35% +$711K ﹤0.01% 3000
2022
Q1
$2.83M Sell
45,648
-2,376
-5% -$141K ﹤0.01% 2917
2021
Q4
$3.38M Sell
48,024
-965
-2% -$68.6K ﹤0.01% 2940
2021
Q3
$3.42M Sell
48,989
-826
-2% -$65.7K ﹤0.01% 2981
2021
Q2
$4.15M Buy
49,815
+1,467
+3% +$104K ﹤0.01% 2964
2021
Q1
$2.64M Sell
48,348
-13,350
-22% -$649K ﹤0.01% 3104
2020
Q4
$2.65M Sell
61,698
-2,577
-4% -$96.2K ﹤0.01% 3051
2020
Q3
$1.94M Buy
64,275
+25,996
+68% +$874K ﹤0.01% 3082
2020
Q2
$1.19M Buy
38,279
+22,400
+141% +$603K ﹤0.01% 3297
2020
Q1
$350K Buy
15,879
+124
+0.8% +$3.36K ﹤0.01% 3538
2019
Q4
$480K Sell
15,755
-90
-0.6% -$2.59K ﹤0.01% 3568
2019
Q3
$487K Sell
15,845
-26,989
-63% -$671K ﹤0.01% 3544
2019
Q2
$857K Sell
42,834
-1,739
-4% -$50.9K ﹤0.01% 3404
2019
Q1
$1.92M Buy
44,573
+251
+0.6% +$9.1K ﹤0.01% 3109
2018
Q4
$1.41M Buy
44,322
+103
+0.2% +$4.06K ﹤0.01% 3227
2018
Q3
$2.32M Buy
44,219
+5,104
+13% +$286K ﹤0.01% 3139
2018
Q2
$2.09M Buy
39,115
+30,218
+340% +$1.55M ﹤0.01% 3185
2018
Q1
$445K Sell
8,897
-165
-2% -$7.4K ﹤0.01% 3603
2017
Q4
$299K Buy
9,062
+521
+6% +$17.6K ﹤0.01% 3684
2017
Q3
$320K Sell
8,541
-80
-0.9% -$2.37K ﹤0.01% 3658
2017
Q2
$220K Buy
8,621
+426
+5% +$10.5K ﹤0.01% 3767
2017
Q1
$213K Buy
8,195
+321
+4% +$9.25K ﹤0.01% 3774
2016
Q4
$240K Buy
7,874
+289
+4% +$7.35K ﹤0.01% 3711
2016
Q3
$206K Buy
7,585
+49
+0.7% +$1.36K ﹤0.01% 3726
2016
Q2
$215K Sell
7,536
-26,089
-78% -$830K ﹤0.01% 3702
2016
Q1
$1.01M Buy
33,625
+223
+0.7% +$6.32K ﹤0.01% 3245
2015
Q4
$1.16M Sell
33,402
-110
-0.3% -$3.76K ﹤0.01% 3271
2015
Q3
$1.27M Buy
33,512
+24,095
+256% +$1.12M ﹤0.01% 3244
2015
Q2
$537K Buy
9,417
+2,584
+38% +$147K ﹤0.01% 3541
2015
Q1
$398K Sell
6,833
-857
-11% -$46K ﹤0.01% 3674
2014
Q4
$436K Sell
7,690
-10
-0.1% -$477 ﹤0.01% 3588
2014
Q3
$315K Sell
7,700
-20,934
-73% -$963K ﹤0.01% 3693
2014
Q2
$1.3M Sell
28,634
-4,814
-14% -$202K ﹤0.01% 3294
2014
Q1
$1.59M Sell
33,448
-2,284
-6% -$104K ﹤0.01% 3239
2013
Q4
$1.68M Sell
35,732
-11,590
-24% -$506K ﹤0.01% 3233
2013
Q3
$1.89M Buy
47,322
+87
+0.2% +$3.42K ﹤0.01% 3122
2013
Q2
$1.68M Buy
+47,235
New +$1.81M ﹤0.01% 3077

Other funds holding HBIO

Northern Trust's HBIO Position: Q1 2026 in Review

Northern Trust sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 9,197 shares — an estimated $61.5K sold.

Northern Trust first reported a position in HBIO in Q2 2013 and held it in 51 quarters. The position peaked at $4.15M in Q2 2021. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Northern Trust reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Northern Trust sold 9,197 Harvard Bioscience shares in Q1 2026, an estimated $61.5K.
  • Northern Trust first reported a position in Harvard Bioscience in Q2 2013 and held it in 51 quarters.
  • Northern Trust's Harvard Bioscience position peaked at $4.15M in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.